TY - JOUR T1 - Phase II Study of Neoadjuvant Gemcitabine, Pegylated Liposomal Doxorubicin, and Docetaxel in Locally Advanced Breast Cancer JF - Anticancer Research JO - Anticancer Res SP - 3817 LP - 3821 VL - 30 IS - 9 AU - ARTIOLI GRAZIA AU - MOCELLIN SIMONE AU - BORGATO LUCIA AU - CAPPETTA ALESSANDRO AU - BOZZA FERNANDO AU - ZAVAGNO GIORGIO AU - ZOVATO STEFANIA AU - MARCHET ALBERTO AU - PASTORELLI DAVIDE Y1 - 2010/09/01 UR - http://ar.iiarjournals.org/content/30/9/3817.abstract N2 - Aim: This was a phase II study to assess the activity of a novel neoadjuvant regimen in locally-advanced breast cancer. Patients and Methods: Fifty patients with histological confirmation of locally advanced breast cancer received treatment with gemcitabine 1000 mg/m2 (day 1) followed by gemcitabine 800 mg/m2 plus docetaxel 75 mg/m2 plus pegylated liposomal doxorubicin (PLD) 30 mg/m2 (day 8) every 3 weeks for at least 4 cycles, plus a final 2 additional cycles. Tumour size was T1 (n=2), T2 (n=32), T3 (n=14), T4 (n=2). All 50 patients underwent surgery. Results: Clinical complete, partial and no response were observed in 13 (26%), 24 (48%) and 11 (22%) patients, respectively (overall response rate: 74%). The number of chemotherapy cycles was found to be an independent predictor of a pathologic complete response. Conclusion: The combination of gemcitabine-docetaxel-PLD can yield high tumour response rates in patients with locally-advanced breast cancer who undergo a full treatment of 6 cycles. ER -